Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
41.18
+0.01 (0.02%)
Jul 15, 2026, 4:00 PM EDT - Market closed
Rigel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 299.77 | 294.28 | 179.28 | 116.88 | 120.24 | 149.24 | |
Revenue Growth (YoY) | 47.61% | 64.15% | 53.38% | -2.79% | -19.43% | 37.39% |
Cost of Revenue | 19.82 | 19.62 | 18.65 | 7.11 | 1.75 | 1.08 |
Gross Profit | 279.95 | 274.66 | 160.63 | 109.77 | 118.49 | 148.15 |
Selling, General & Admin | 118.84 | 115.9 | 113.06 | 105.74 | 112.45 | 91.89 |
Research & Development | 36.54 | 33.3 | 23.38 | 24.52 | 60.27 | 65.24 |
Other Operating Expenses | - | - | - | - | 1.32 | 3.52 |
Total Operating Expenses | 155.37 | 149.2 | 136.44 | 130.26 | 174.04 | 160.65 |
Operating Income | 124.58 | 125.47 | 24.19 | -20.49 | -55.55 | -12.5 |
Interest Income | 4.3 | 3.68 | 2.09 | 2.27 | 0.68 | 0.05 |
Interest Expense | -6.9 | -7.32 | -7.92 | -6.87 | -3.71 | -4.86 |
Total Non-Operating Income (Expense) | -2.61 | -3.64 | -5.83 | -4.6 | -3.02 | -4.81 |
Pretax Income | 121.97 | 121.83 | 18.37 | -25.09 | -58.57 | -17.31 |
Provision for Income Taxes | -242.26 | -245.2 | 0.88 | - | - | 0.61 |
Net Income | 364.23 | 367.02 | 17.49 | -25.09 | -58.57 | -17.91 |
Net Income to Common | 364.23 | 367.02 | 17.49 | -25.09 | -58.57 | -17.91 |
Net Income Growth | 879.70% | 1999.08% | - | - | - | - |
Shares Outstanding (Basic) | 18 | 18 | 18 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 19 | 19 | 18 | 17 | 17 | 17 |
Shares Change (YoY) | 7.63% | 6.52% | 1.64% | 2.07% | -0.00% | 1.03% |
EPS (Basic) | 20.07 | 20.40 | 0.99 | -1.44 | -3.44 | -1.10 |
EPS (Diluted) | 18.72 | 19.48 | 0.99 | -1.44 | -3.44 | -1.10 |
EPS Growth | 804.35% | 1867.68% | - | - | - | - |
Free Cash Flow | 79.29 | 75.66 | 31.44 | -5.74 | -74.21 | 5.25 |
Free Cash Flow Growth | 4.80% | 140.67% | - | - | - | - |
Free Cash Flow Per Share | 4.13 | 4.02 | 1.78 | -0.33 | -4.35 | 0.31 |
Gross Margin | 93.39% | 93.33% | 89.60% | 93.92% | 98.55% | 99.27% |
Operating Margin | 41.56% | 42.63% | 13.49% | -17.53% | -46.20% | -8.37% |
Profit Margin | 121.50% | 124.72% | 9.75% | -21.47% | -48.71% | -12.00% |
FCF Margin | 26.45% | 25.71% | 17.53% | -4.91% | -61.72% | 3.52% |
EBITDA | 126.99 | 127.88 | 26.42 | -19.25 | -54.55 | -11.33 |
EBITDA Margin | 42.36% | 43.46% | 14.74% | -16.47% | -45.37% | -7.59% |
EBIT | 124.58 | 125.47 | 24.19 | -20.49 | -55.55 | -12.5 |
EBIT Margin | 41.56% | 42.63% | 13.49% | -17.53% | -46.20% | -8.37% |
Effective Tax Rate | -198.62% | -201.27% | 4.80% | 0.00% | 0.00% | -3.50% |